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ABSTRACT
Background: Infection and mortality rates are greater in women than in men after cardiac
surgery. This study was conducted to assess whether allogeneic blood transfusion could par-
tially account for this gender difference, as transfusion has been associated with im-
munomodulation.
Methods: A cohort study was conducted in 380 patients at the University of Rochester Med-
ical Center. Subjects were adult patients who underwent primary coronary artery bypass graft
(CABG) surgery, primary valve replacement surgery, or both. Information was collected about
blood components transfused, as well as postoperative infection, pulmonary dysfunction, and
in-hospital mortality.
Results: Women were more likely to receive allogeneic red blood cells (RBCs) or platelets
than men (odds ratio [OR] 21.6, 95% CI 3.8, 124.2) and a greater quantity of blood than men.
Patients who received allogeneic blood were 4.4 times more likely to develop an infection
than those who did not (95% CI 1.5, 13.2). There was a positive linear correlation between
number of units of blood received and number of days with fever (p  0.001) and hospital
length of stay (p  0.001). This was particularly evident in patients who received four or more
units of nonleukoreduced blood components. Women had a greater risk of infection (p 
0.005), pulmonary dysfunction (p  0.005), and mortality (p  0.007) than men during hospi-
talization.
Conclusions: One reason for the greater mortality in women after cardiac surgery may be
the increased likelihood of receiving nonleukoreduced allogeneic RBCs and platelets. Trans-
fusion increased the risk of infection; infection, then, increased the likelihood of pulmonary
dysfunction and mortality. 
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INTRODUCTION
IN A RECENT REVIEW on revascularization in wo-men, the author stated: “Although our under-
standing of the gender differences in outcomes
following coronary revascularization has in-
creased, what is missing is a clear concept of how
these gender paradoxes translate into increased
morbidity and mortality in women.”1 We report
here evidence suggesting an explanation for this
gender gap in morbidity and mortality after car-
diac surgery.
The pathway leading to greater mortality in
women may begin with the decision to adminis-
ter a blood transfusion. Blood transfusion is the
most common procedure during hospitalization,
and its use has increased 64% from 1997 to 2003.2
Cardiac surgery accounts for approximately 20%
of all allogeneic blood transfusions in the United
States, although there is considerable variability
among hospitals regarding the amount of blood
components administered.3 Although transfu-
sion may be necessary to prevent or treat tissue
hypoxia, the immunomodulatory effects of allo-
geneic blood transfusion have been recognized
for decades.4–6 Transfusion-related immunomod-
ulation has been shown to result in an increased
risk of nosocomial infection and mortality in var-
ious patient cohorts.7–13
The proposed causal pathway is of particular
import to women, as the decision to prescribe a
transfusion conventionally rests on threshold lev-
els of hemoglobin or hematocrit. Normal hemo-
globin and hematocrit levels are lower in women,
and, thus, women are more likely than men 
to receive a transfusion.14,15 We studied this path-
way, from female gender to transfusion to infec-
tion to mortality, in patients who underwent 
cardiac surgery and hypothesized that this mech-
anism may account for some of the increased
mortality risk observed in women.
MATERIALS AND METHODS
Subjects were patients who underwent pri-
mary coronary artery bypass graft (CABG)
surgery, primary valve replacement surgery, or
both at the University of Rochester Medical Cen-
ter in Rochester, New York, from July 1 to De-
cember 31, 1997 or from July 1 to December 31,
1998. Eligibility was restricted to adults (18
years of age). Operations were performed by two
surgeons with long-established practices at the
institution.
Information was collected from cardiothoracic
division records, as well as the transfusion ser-
vice, laboratory information system, and patient
medical records. Abstraction of information from
the cardiothoracic division was blinded to the
type of transfusion received. Demographic data
were compiled regarding age at the time of
surgery, body mass index (BMI), sex, race (white,
other), and ethnicity (Hispanic, non-Hispanic).
Data were also recorded regarding urgency of
surgery (elective, urgent, emergency), preopera-
tive hematocrit, ejection fraction, and comorbidi-
ties (diabetes mellitus, renal disease, hyper-
cholesterolemia, hypertension, coronary artery
disease [CAD], family history of CAD, history of
myocardial infarction [MI], congestive heart fail-
ure [CHF], chronic obstructive pulmonary dis-
ease [COPD], and peripheral vascular disease).
Numbers of units of transfused blood compo-
nents were obtained from the transfusion service,
as was information regarding filtration of leuko-
cytes (yes or no). Leukoreduction of red blood
cells (RBC) was conducted by filtration prior to
storage at the regional blood supplier. Leukore-
duction of whole blood-derived platelet concen-
trates was conducted by filtration after storage
and immediately prior to transfusion. Leukore-
duced products decreased the leukocyte count by
approximately 99.9% for both prestorage-filtered
RBCs and poststorage-filtered platelets.
Outcomes included in-hospital mortality, total
length of stay in the hospital (days), number of
hours in the intensive care unit, diagnosis of in-
fection (all sites combined), number of days of
fever (temperature 37°C), days of antibiotic
therapy, and diagnosis of pulmonary dysfunc-
tion. Pulmonary dysfunction was defined opera-
tionally as any pulmonary failure or dysfunction
that delayed extubation postoperatively beyond
48 hours or required reintubation. Definition of
pulmonary dysfunction in general also required
that imaging studies reflect bilateral pathology,
no CHF, dysfunction lasting 72 hours, and ar-
terial oxygen pressure 200 mm.
The analyses were structured to assess the re-
lationships among factors in the proposed causal
pathway, from gender to transfusion to infection
to pulmonary dysfunction to mortality. Categor-
ical data were initially examined using Pearson’s
chi-square test or Fisher’s exact test (for data with
5 expected observations/cell). Differences in
means were determined using Student’s t-test,
preceded by F tests for differences in variance.
Exact binomial 95% confidence intervals (CI)
were calculated for proportions. Pearson prod-
uct-moment correlation coefficients were used to
assess the strength of the association between
units of blood received and continuous outcomes.
Imputation by best-subset regression was per-
formed for demographic variables with missing
values prior to fitting models; this occurred in
0.5% of the subjects. Generalized linear regression
models were used to model the relation between
predictors and outcomes, with Newton-Raphson
maximum likelihood optimization and clustering
by attending surgeon. For continuous outcomes,
a Gaussian distribution was used with an iden-
tity-link function. Adjusted means were centered
on the mean age (67 years) and mean BMI (28
kg/m2). For dichotomous outcomes, a binomial
distribution with a logit-link function was used.
Robust (Huber/White/sandwich) estimators of
variance were calculated. Alpha was set at 
0.05, 2-tailed. Stata/SE 9.2 was used for the analy-
ses.
RESULTS
There were 380 subjects, 60.5% men and 39.5%
women. Women were more likely than men to be
older, Hispanic, and have CHF (Table 1). Women
were also more likely to receive valve repair or
CABG with valve repair than men in this patient
population (p  0.003). Women were more evenly
distributed across BMI categories than men (p 
0.015), although mean BMI was similar in the two
groups (mean 28.0 kg/m2, standard deviation [SD]
5.9 for women; mean 27.9 kg/m2, SD 4.6 for men;
p  0.9036). At the extremes of this distribution,
there were fewer patients with low BMI of 18.5
(3 women and 1 man) than patients with BMI40,
indicating morbid obesity (5 women and 7 men).
ROGERS ET AL.1414
TABLE 1. CHARACTERISTICS OF PATIENTS BY GENDER
Women Men
n  150 n  230
Characteristic n (%) n (%) p value
Age, years
60 22 (14.7%) 61 (26.5%)
60–69 32 (21.3%) 81 (35.2%)
70–79 69 (46.0%) 70 (30.4%)
80 27 (18.0%) 18 (7.8%) 0.01
Race, white 139 (92.7%) 218 (94.8%) 0.40
Ethnicity, non-Hispanic 143 (95.3%) 227 (98.7%) 0.05
BMI, kg/m2
25 52 (34.7%) 57 (24.8%)
25–29.9 51 (34.0%) 112 (48.7%)
30 47 (31.3%) 61 (26.5%) 0.01
Urgency of surgery
Elective 60 (40.3%) 99 (43.0%)
Urgent 80 (53.7%) 106 (46.1%)
Emergency 9 (6.0%) 24 (10.4%) 0.27
Type of surgery
CABG 86 (57.3%) 170 (73.9%)
Valve repair 29 (19.3%) 24 (10.4%)
CABG and valve repair 35 (23.3%) 36 (15.7%) 0.01
Diabetes mellitus 56 (37.3%) 70 (30.4%) 0.16
Renal disease 25 (16.7%) 37 (16.1%) 0.88
Hypercholesterolemia 81 (54.0%) 126 (54.8%) 0.88
Hypertension 111 (74.0%) 151 (65.7%) 0.09
History of coronary artery disease 108 (72.0%) 171 (74.3%) 0.61
Family history of coronary artery disease 78 (52.0%) 123 (53.5%) 0.78
History of myocardial infarction 61 (40.7%) 111 (48.3%) 0.15
Ejection fraction 40% 112 (75.2%) 179 (78.5%) 0.45
Congestive heart failure 71 (47.3%) 50 (21.7%) 0.01
Chronic obstructive pulmonary disease 18 (12.0%) 39 (17.0%) 0.19
Peripheral vascular disease 22 (14.7%) 40 (17.4%) 0.48
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Gender and transfusion
Of the 150 women, 99.3% (n  149) received al-
logeneic RBCs or platelets during hospitalization
for cardiac surgery. This compares with 77.0% of
men (p  0.001). The odds that a woman would
receive a transfusion were 44.6 times greater than
for a man (95% CI 5.0, 394.4) (Table 2). When ad-
justed for demographic and clinical factors, in-
cluding BMI, the odds ratio (OR) was 34.0 (95%
CI 3.8, 303.7), and with further adjustment for
preoperative hematocrit, the OR remained sig-
nificant at 21.6 (95% CI 3.8, 124.2).
Although preoperative hematocrit did affect
the likelihood of receiving a blood transfusion, it
had less of an effect on women than men. Ninety-
two percent of men with low preoperative hema-
tocrit (41%) and 100% of women with low
hematocrit (38%) were given at least one unit
of RBCs or platelets during hospitalization. In
contrast, 62% of men with normal preoperative
hematocrit (41%–50%) received blood, and 99%
of women with normal preoperative hematocrit
(38%–50%) had a transfusion (p  0.001). Figure
1 shows the percentage of patients who received
four or more units of RBCs during hospitaliza-
tion by gender and preoperative hematocrit. In
women whose preoperative hematocrit was nor-
mal, 40%–50% received four or more units of
RBCs during the course of their hospitalization.
Women were more likely than men to receive
a greater quantity of blood, regardless of the type
of allogeneic blood received. The mean number
of units of unfiltered blood (RBCs or platelets or
both) transfused in women was 9.2 (95% CI 7.3,
11.2) compared with 6.3 units (95% CI 4.7, 8.0) in
men (p  0.024). The mean number of units of
whole blood-derived random donor platelets re-
ceived by women was 16.0 (95% CI 6.9, 25.0) com-
pared with 6.7 units (95% CI 5.5, 7.8) in men (p 
0.021). The mean number of units of prestorage
leukoreduced RBCs received by women was 4.9
(95% CI 3.9, 5.8) compared with 3.0 units (95% CI
2.3, 3.7) in men (p  0.001).
Gender and outcomes
Women were more likely than men to be di-
agnosed with infection (p  0.005) or pulmonary
dysfunction (p  0.005) and to die during hospi-
talization (p  0.007) (Table 3). While 6.7% of wo-
men died while in the hospital, 1.3% of men died
yielding a risk ratio of 5.1 (95% CI: 1.4, 18.3). Ap-
proximately 11% of women developed pul-
monary dysfunction compared with 3.9% of men
(risk ratio  2.9, 95% CI 1.3, 6.3). The mean num-
ber of hours spent in an intensive care unit was
longer in women than in men (129.3 hours vs. 65.3
hours, respectively, p  0.032). The mean length
of stay in the hospital was also greater in women
TABLE 2. ASSOCIATION BETWEEN PREDICTORS AND OUTCOMES IN PROPOSED CAUSAL PATHWAY
Predictor Outcome Unadjusted OR 95% CI Adjusted ORa 95% CI
Female sex Transfusionb 44.6 5.0, 394.4 34.0 3.8, 303.7
Transfusionb Infection 10.7 3.7, 30.6 4.4 1.5, 13.2
Infection Pulmonary dysfunction 46.2 9.4, 227.4 20.5 4.4, 95.6
Pulmonary dysfunction Death 46.3 37.5, 57.2 246.9 23.5, 2595.6
aAdjusted for age, race, ejection fraction, surgical priority, type of surgery (CABG, valve repair or both), body mass
index, diabetes, renal disease, history of coronary artery disease, history of myocardial infarction, congestive heart
failure, and chronic obstructive pulmonary disease.
bTransfusion of red blood cells or platelets.
FIG. 1. Percentage of surgical patients who received
four or more units of red blood cells during hospitaliza-
tion, by preoperative hematocrit and gender.
(16.2 days) compared with men (10.5 days) (p 
0.001).
Transfusion and infection
Patients who received RBCs or platelets were
10.7 times as likely to develop an infection dur-
ing hospitalization as patients who did not re-
ceive these blood components (95% CI 3.7, 30.6,
p  0.001) (Table 2). With adjustment for demo-
graphic and clinical factors, the OR for the rela-
tion between transfusion and infection was 4.4
(95% CI 1.5, 13.2, p  0.009).
There was a positive linear correlation between
number of units of blood (RBCs or platelets or
both) received and the number of days of fever
during hospitalization; the correlation coefficient
was 0.709 (p  0.001). The correlation coefficient
increased to 0.771 (p  0.001) for nonleukore-
duced, unfiltered blood only. Similarly, the cor-
relation between number of units of RBCs or
platelets or both transfused and number of days
on antibiotic medication was significant (r 
0.697, p  0.001), and when only nonleukore-
duced unfiltered blood was considered, the cor-
relation coefficient was 0.758 (p  0.001). The
number of hours spent in an intensive care unit
increased with the number of units of blood re-
ceived (r  0.474, p  0.001), and the association
was stronger when only nonleukoreduced blood
was given (r  0.726, p  0.001). This was similar
to the pattern for hospital length of stay (r 
0.494, p  0.001 for all units of RBCs or platelets
or both; r  0.793, p  0.001 for nonleukore-
duced, unfiltered blood only). 
Mortality
Of the 380 patients, 13 died while in the hos-
pital (3.4%). All the patients who died had re-
ceived a blood transfusion. Infection was strongly
associated with both mortality (p  0.001) and
pulmonary dysfunction (p  0.001). When ad-
justed for demographic and clinical factors, the
OR for the relation between infection and pul-
monary dysfunction was 20.5 (95% CI 4.4, 95.6,
p  0.001), and the OR for the association be-
tween pulmonary dysfunction and death was
246.9 (95% CI 23.5, 2595.6, p  0.001) (Table 2).
Outcomes by type of transfusion
Both quantity and type of transfusion (leuko-
reduced and nonleukoreduced) affected out-
comes (Table 4). Patients who received either no
units or less than four units of RBCs or platelets
or both had the lowest risk of mortality. Mortal-
ity was highest (10.5%) in patients who received
four or more units of either RBCs or platelets,
some of which were unfiltered. In this group, the
mean number of units of unfiltered RBCs was 9.6
and of unfiltered platelets was 1.4. These patients
were disproportionately women; 32% of women
received this type of transfusion compared with
16.5% of men.
Compared with patients without a blood trans-
fusion, the number of days with fever was sig-
nificantly greater for those patients who received
four or more units of blood components, with the
exception of those who received only prestorage
filtered RBCs. Patients who received four or more
units of RBCs and platelets (some unfiltered) had
a significantly increased number of days with
fever (8.8 days) compared with patients without
a transfusion (3.3 days, p  0.001) and had a sig-
nificantly increased number of days with fever
compared with those who received four or more
units of RBCs and platelets, all of which was fil-
tered (6.3 days, p  0.001). Filtering also appeared
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TABLE 3. DIFFERENCES IN OUTCOMES BY GENDER
Women Men
% or mean 95% CI % or mean 95% CI p value
Infection 33.3% 25.9, 41.5 20.4% 15.4, 26.2 0.01
Mean days with fever 6.6 5.0, 8.2 5.3 4.2, 6.5 0.21
Mean days on antibiotics 6.0 3.4, 8.6 4.2 1.9, 6.6 0.33
Mean hours in intensive care 129.3 70.2, 188.4 65.3 37.3, 93.2 0.03
Mean length of stay 16.2 12.6, 19.8 10.5 8.9, 12.1 0.01
Pulmonary dysfunction 11.3% 6.7, 17.5 3.9% 1.8, 7.3 0.01



















































































































































































































































































































































































































































































































































































































































































































































































































































to reduce the number of days with fever for those
who received one to three units. There was an in-
crease (from 3.4 to 4.9 days) in the mean number
of days with fever for patients who received one
to three units of unfiltered vs filtered RBCs (p 
0.001). Likewise, there was an increase (2.9 to 6.0
days) in the mean number of days with fever for
those who received one to three units of unfil-
tered vs. filtered RBCs and platelets (p  0.001).
There was considerable variation in the num-
ber of days on antibiotics. Although the mean
number of days on antibiotics ranged from 3.1 to
13.9 in patients who received four or more units
of various types of blood components, none were
significantly different from the mean for patients
without a transfusion (mean of 1.6 days). The ex-
ception was patients who received one to three
units of unfiltered RBCs and platelets, whose
mean number of days on antibiotics was 3.2 (p 
0.031).
The mean number of hours spent in an inten-
sive care unit tended to increase with an increas-
ing number of units of blood transfused. Patients
who were transfused with four or more units of
either unfiltered RBCs only (64 hours, p  0.001)
or filtered RBCs and platelets (106.5 hours, p 
0.043) spent a greater number of hours in inten-
sive care than did patients without a transfusion
(44.1 hours). Although the mean number of hours
in the intensive care unit was 154 for those re-
ceiving four or more units of unfiltered RBCs and
platelets, the difference was of marginal signifi-
cance (p  0.085) when compared with patients
with no transfusion.
Hospital length of stay was greater in patients
who received four or more units of either unfil-
tered RBCs only (10.3 days, p  0.001), filtered
RBCs and platelets (13.6 days, p  0.001), or un-
filtered RBCs and platelets (17.2 days, p  0.002)
compared with patients without a transfusion
(7.1 days).
DISCUSSION
In this study, women experienced greater in-
fection and mortality after cardiac surgery com-
pared with their male counterparts. This may be
due, at least in part, to the type and quantity of
blood transfusion received. Women were more
likely than men to receive an allogeneic blood
transfusion as well as greater quantities of blood,
even after consideration of preoperative hemat-
ocrit, age, BMI, and clinical presentation. Allo-
geneic RBC and platelet transfusions were
strongly associated with an increased risk of in-
fection, pulmonary dysfunction, and death, par-
ticularly when nonleukoreduced blood was ad-
ministered.
The relation between gender and transfusion
has been reported and, similar to what we found
here, remained after consideration of hematocrit
levels.14 In a systematic review, female gender,
preoperative anemia, advancing age, and small
body size were found to be the most common pre-
dictors of perioperative allogeneic RBC transfu-
sion.16
The risk of a poor outcome was greatest in
those who received four or more units of either
nonleukoreduced RBCs or who received any
platelet transfusions. In a nationwide study of pa-
tients in intensive care units, a greater number of
RBCs transfusions has been shown to be an in-
dependent predictor of longer stay in the inten-
sive care unit and increased length of hospital
stay, as well as increased mortality.17 Thirty-day
mortality was 4-fold greater in patients who re-
ceived more than four units of RBCs compared
with patients without a transfusion. Furthermore,
the use of restrictive criteria for transfusion, and
thus reduced use of allogeneic blood, was shown
to be just as effective as liberal criteria in critically
ill and surgical patients, although the current ev-
idence in cardiac patients is not yet sufficient.18–20
In a large population-based study in Canada
prior to the implementation of universal leuko-
reduction of allogeneic blood, an increased risk
of mortality in women was evident only within
30 days after the CABG procedure but not in the
subsequent 10 years.21 Therefore, it is possible
that the risk of infection from allogeneic blood
may be short term; if so, it is during this period
that vigilance about infection control would be
most appropriate. Given that approximately
41%–71% of all Americans have a blood transfu-
sion within their lifetimes, the effect of this ex-
posure and the time at-risk for infection needs ad-
ditional study.22
An association between transfusion and lung
injury has been reported, and a rare consequence,
transfusion-related acute lung injury, carries a
5%–10% risk of mortality.23 In a study of patients
in four intensive care units at the Mayo Clinic, 7%
of those who received transfusions developed
respiratory failure within 6 hours of the transfu-
sion.24 Although mechanisms underlying these
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relationships were not a part of this investigation,
proinflammatory agents in stored blood compo-
nents, particularly platelets, have been impli-
cated.25 For example, soluble CD40 ligand, a
proinflammatory protein that accumulates dur-
ing storage, has been shown to activate poly-
morphonuclear leukocytes in patients and may
cause pulmonary endothelial damage and trans-
fusion-related acute lung injury.26 Allogeneic
blood has been shown to alter cytokine levels, in-
crease humoral immunity, and decrease cell-me-
diated immunity.27 Immunological effects of al-
logeneic blood have been recognized since the
1970s and, since then, have been used to enhance
graft survival in patients with solid organ trans-
plants, particularly before the widespread use of
immunosuppressant medications.4,28
Limitations
We were unable to assess the independent ef-
fects of platelets, as they were almost exclusively
administered with RBCs in this population. Sim-
ilarly, we could not assess the effects of prestor-
age vs. poststorage filtration because the type of
filtration was unique to the particular blood com-
ponent; all filtering of RBCs was conducted prior
to storage, whereas all filtering of platelets was
conducted after storage. Our data did show, how-
ever, that filtered blood components tended to
decrease the number of days with fever compared
with unfiltered blood. In addition, the data sug-
gest that larger quantities of unfiltered RBCs and
platelets result in a longer hospital stay and
higher mortality.
As this study was not a randomized, controlled
trial, we were unable to determine if the relation
between transfusion and infection was due to
confounding by indication; that is, the underly-
ing reasons for prescribing a transfusion, and not
the transfusion itself, may lead to detrimental
outcomes. Fergusson et al.29 conducted a meta-
analysis of the randomized, controlled trials in
cardiac surgical patients who received leukore-
duced vs. nonleukoreduced blood transfusion.
They found an overall reduction in postoperative
infection for patients receiving leukoreduced
blood. Bilgin et al.30 also found a significant re-
duction in the infection rate in patients who re-
ceived leukocyte-depleted erythrocytes (com-
pared with buffy coat-depleted erythrocytes) in a
randomized controlled trial of patients who un-
derwent cardiac valve surgery. These studies, be-
cause of their randomized design, provide evi-
dence that confounding by clinical indication is
not likely to explain improved patient outcomes
with leukoreduced transfusion.
CONCLUSIONS
Immunomodulation from the receipt of non-
leukoreduced allogeneic blood may increase the
risk of infection, pulmonary dysfunction, and
mortality during hospitalization for cardiac
surgery. This is of particular significance for wo-
men, who are more likely to receive a greater
quantity of blood than men. Measures should be
taken to encourage research in alternatives to
nonleukoreduced allogeneic blood and to in-
crease infection control procedures during the pe-
riod of immunomodulation. Wider use of leuko-
reduced RBC transfusions and multimodal
approaches to blood conservation and anemia
prevention, as in bloodless medicine and surgery
programs, may provide particular benefit to wo-
men.31
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